Skip to main content

Table 1 Relative potency (compared to biosimilar) of originators in ADCC and CDC assays

From: Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions

Assay

Originator

Relative potency

CV

ADCC

2

140%

9.9%

 

3

141%

11.1%

 

4

135%

16.8%

CDC

2

92%

15.1%

 

3

89%

10.2%

 

4

89%

16.7%